IQVIA Holdings/$IQV
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About IQVIA Holdings
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Ticker
$IQV
Sector
Primary listing
NYSE
Employees
91,000
Headquarters
Website
IQVIA Holdings Metrics
BasicAdvanced
$36B
28.82
$7.30
1.38
-
Price and volume
Market cap
$36B
Beta
1.38
52-week high
$225.00
52-week low
$134.65
Average daily volume
1.7M
Financial strength
Current ratio
0.703
Quick ratio
0.621
Long term debt to equity
207.156
Total debt to equity
241.571
Interest coverage (TTM)
3.21%
Profitability
EBITDA (TTM)
2,926
Gross margin (TTM)
33.78%
Net profit margin (TTM)
8.07%
Operating margin (TTM)
14.26%
Effective tax rate (TTM)
19.19%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
5.07%
Return on equity (TTM)
19.37%
Valuation
Price to earnings (TTM)
28.817
Price to revenue (TTM)
2.305
Price to book
5.82
Price to tangible book (TTM)
-2.47
Price to free cash flow (TTM)
16.579
Free cash flow yield (TTM)
6.03%
Free cash flow per share (TTM)
12.694
Growth
Revenue change (TTM)
3.85%
Earnings per share change (TTM)
-4.16%
3-year revenue growth (CAGR)
3.59%
10-year revenue growth (CAGR)
14.08%
3-year earnings per share growth (CAGR)
5.89%
10-year earnings per share growth (CAGR)
9.57%
What the Analysts think about IQVIA Holdings
Analyst ratings (Buy, Hold, Sell) for IQVIA Holdings stock.
Bulls say / Bears say
IQVIA narrowed its 2025 adjusted EPS forecast to $11.85–$11.95 from $11.75–$12.05 as it anticipates continued cancellations of pharmaceutical research contracts, highlighting persistent headwinds in its core CRO business (Reuters).
Analysts caution that clinical trial demand has not fully recovered despite a recent stabilization, with concerns over tight biotech funding and policy-driven risks such as tariffs and U.S. drug pricing reforms potentially dampening future bookings (Reuters).
IQVIA’s Technology & Analytics Solutions unit reported Q3 sales of $1.63 billion, missing the $1.66 billion consensus estimate, underscoring potential challenges in its high-growth segment amid tightening R&D budgets (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
IQVIA Holdings Financial Performance
Revenues and expenses
IQVIA Holdings Earnings Performance
Company profitability
IQVIA Holdings News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IQVIA Holdings stock?
IQVIA Holdings (IQV) has a market cap of $36B as of November 08, 2025.
What is the P/E ratio for IQVIA Holdings stock?
The price to earnings (P/E) ratio for IQVIA Holdings (IQV) stock is 28.82 as of November 08, 2025.
Does IQVIA Holdings stock pay dividends?
No, IQVIA Holdings (IQV) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next IQVIA Holdings dividend payment date?
IQVIA Holdings (IQV) stock does not pay dividends to its shareholders.
What is the beta indicator for IQVIA Holdings?
IQVIA Holdings (IQV) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.